The Swiss pharmaceutical Roche group decided to close the production of medicines in Brazil. In a statement, the company reported that the activities of its factory, located in Jacarepaguá, in Rio de Janeiro, should be closed completely between four and five years.
Roche Farma Brasil, the division of the group in the country, will maintain its headquarters and administrative office in São Paulo and its distribution center in Anápolis (GO).
According to the company, there are no forecasts to reduce the number of employees in Rio de Janeiro in 2019, due to the announcement. Currently there are 440 employees in the unit.
"Our employees will receive the best possible support, with a transparent and respectful treatment, throughout this transition period," said Patrick Eckert, president of Roche Farma Brasil, in a statement.
The company attributed the decision to the global strategy of "focusing efforts on innovative products with high complexity and low production volumes."
According to Roche, drugs currently produced in the country (Bactrim, Bonviva, Cymevene, Dilatrend, Dormonid, Lexotan, Prolopa, Rivotril, Rocaltrol, Rohypnol and Valium) consist of high volume and low complexity products, "which makes Rio de Janeiro little sustainable ".
"Roche reinforces its commitment to continue providing patients with the high quality medicines that are now manufactured in Rio," he added.
The company informs its website that has 1,200 employees throughout the entire operation in Brazil.